^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR-1501

    i
    Other names: SHR-1501, SHR1501, SHR 1501
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    IL-15R agonist
    Related drugs:
    Associations

    News

    Trials
    3ms
    SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt (clinicaltrials.gov)
    P1/2, N=58, Not yet recruiting, Fudan University
    New P1/2 trial
    |
    SHR-1501
    2years
    A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    Ariely (adebrelimab) • SHR-1501
    over2years
    A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Active, not recruiting | N=104 --> 14 | Trial completion date: Jun 2023 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Sep 2022
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD8 (cluster of differentiation 8)
    |
    Ariely (adebrelimab) • SHR-1501